**Sample Other Support, 11/30/2020**

**For New and Renewal Applications – DO NOT SUBMIT UNLESS REQUESTED**

**PHS 398 OTHER SUPPORT**

**Fitzgerald, E.**

**SPONSORED RESEARCH AWARDS**

ACTIVE (domestic)

**BMC**

5R01 HL 107900-04 (Fitzgerald) 4/1/2017 – 3/31/2022 3.0 CM

NIH/NHLBI $2,100,000 cumulative total costs

 ($250,000 total direct annually)[[1]](#footnote-1)

Ion Transport in Lungs

The major goal of this project is to study chloride and sodium transport in normal and diseased lungs.

BMC Pulmonary Department 12/21/2019-5/21/2021 .6 CM

 $86,250 cumulative total costs

 ($75,000 total direct annually)

Gene Therapy for Small Cell Lung Carcinoma

This award provides pilot funding for a promising project.

Industry Sponsored Clinical Trials Aggregated Effort 1.8 CM

Each off these individual projects has a varying need of effort depending on the type of activity currently in progress: protocol development, start-up, patient recruitment, enrollment, follow-up, monitoring, data analysis, publication, and closeout, Faculty determines each project’s need and adjust their effort between projects within the total aggregated effort assigned to the clinical projects. Effort is reviewed and confirmed by the department based on the activity of each project.

Crosby Pharmaceuticals Corporation (Fitzgerald) 10/1/2018-9/30/2021

Parameters in Early Detection of CHI $954,546 cumulative total costs

The major goals of this project are to use viral strategies to express the normal p01 gene in human TCLC cell lines and to study the effect on growth and invasiveness of the lines.

Role: Co-Investigator

Simone Pharmaceuticals, Inc. (Fitzgerald) 02/25/2019-8/31/2021

Analysis Patients vs. Doctors $675,000 cumulative total costs

The major goals of this project are to determine how contributions to lung function decline

Role: Co-Investigator

**Boston University**

European Commission (Holiday) 9/1/2018-8/31/2021 1.2 calendar months

 $1,200,000 cumulative total costs for BU sub

 ($363,636 total direct annually)

Network for Drug Discovery to Address Pulmonary Vascular Disease

The major goal of the network is to accelerate the discovery of small molecules that have the potential to treat PVD.

PENDING

**BMC**

DCB 950000 (Vedder) 12/1/2019-11/30/2021 1.2 CM

National Science Foundation $437,824 cumulative total costs

 ($130,304 annual total direct costs)

Liposome Membrane Composition and Function

The major goals of this project are to define biochemical properties of liposome membrane components and maximize liposome uptake into cells.

*The proposal under consideration*

R01-HL110456-01A1 (Fitzgerald) 9/1/2019-8/31/2024 2.4 CM

NIH $607,008 cumulative total costs

 ($112,409 annual total direct costs)

Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension

The major goals of this project are to explore the delivery of genetic material to enhance release of drugs at specific sites.

**FOREIGN AND DOMESTIC RESOURCES (other commitments and support not listed above)**

**DOMESTIC**

**Service Agreements**

A Big Pharma, Inc. $15,000 for 3-month period of 10/20/20 to 12/30/20

Served as expert witness in congressional testimony

**External Research Activity**

Merck & Smerck Incorporated $25,000 for 3-month period of 12/20/19 to 3/20/20

Will be paid consultant exploring uses for their therapeutics and Coronavirus for Merck and Smerck’s research program.

**Start-Up Funds from Non-BMC domestic entities**

**In-Kind Lab or Office Space**

Boston University

I have office space and 750 sq feet of state-of-the-art wet-lab space. *These facilities will not be employed for the pending proposal.*

**Scientific Materials (biological materials, supplies, or equipment – In-Kind Dollar Amount valuation)**

ThermoFisher Scientific (Fitzgerald) 7/1/2018-6/30/2022

This agreement allows my lab to use a Orbitrap ID-X Tribrid Mass Spectrometer at no cost. *This equipment will not be employed for the pending proposal.*

**Collaboration**

BMC

Starr, T. University College London. 9/2015-present

Professor Starr is a frequent collaborator who runs analyses at no cost for me on his cohort of patients with Pulmonary Arterial Hypertension. The cohort includes both a repository of lung tissue and rich data sets. *This collaboration is necessary for the pending proposal’s project.*

**Visiting faculty/scholars/scientists/post-docs**

BMC

 C. Cornell 1/01/2019-12/31/2021 $120,000 cumulative total

 Cystic Fibrosis Foundation Individual Fellowship

 Visiting scholar from UCSF

The major goal is to develop a better understanding of the developmental malfunctions that contribute to Cystic Fibrosis. *This fellowship is not related to the pending proposal.*

**Students (Undergraduate and Graduate)**

One undergraduate and one graduate students paid from sources other than my research, on scholarships or stipends from their home institutions. All assisting on two of my grants

**Gifts (Not required but list them if used to subsidize expenses for your research)**

Ford Foundation Approximate Value: $300,000

Used to purchase equipment and subsidize staff salaries related to my research work

**FOREIGN**

**Service Agreements**

None.

**External Research Activity**

University of Switzerland $15,000 for 2-month period of 8/1/20 – 9/30/20Served as paid consultant exploring pulmonary effects for a Coronavirus project

**Start-Up Funds from Non-BMC domestic entities**

Fuzhou University (ACTIVE)

Start-up funds 10/01/2018-9/30/2022 no effort

 $500,000 cumulative total costs

This is flexible start-up funding to start a lab at JNU to focus on small molecule discovery to develop drug leads to address unmet medical needs in pulmonary health.

**In-Kind Lab or Office Space**

Fuzhou University

I have a 1000 square feet of wet lab space outfitted with state-of-the-art microscopy.

working on projects in my lab. *These facilities will not be employed for the pending proposal.*

**Scientific Materials (biological materials, supplies, or equipment – In-Kind Dollar Amount valuation)**

Guanzhou University

I am allowed to access high throughput chemical screening facilities and a mass spectrometer. I have one graduate student working on projects in my lab. *These facilities will not be employed for the pending proposal.*

**Collaboration**

Fuzhou University

I am collaborating with Fuzhou University and may include other institutions in China in the future on a project, not related to the pending proposal. I will update my Other Support page if this does change.

**Visiting faculty/scholars/scientists/post-docs**

N. Young 1/01/2020-12/31/2022 $100,000 cumulative total

Post-doc from McCanada University

Canadian Institutes of Health Research Fellowship Award

The major goal is to explore the delivery of genetic material to enhance release of drugs at specific sites. *This fellowship is paid directly to Dr. Young. This fellowship is directly related to the pending proposal, as Dr. Young, a postdoctoral fellow in my lab, is proposed to carry out Aims 1 and 2.*

**Students (Undergraduate and Graduate)**

Fuzhou University

I have one graduate student working on projects in my lab. *These facilities will not be employed for the pending proposal.*

**Gifts (Not required but list them if used to subsidize expenses for your research)**

None.

**POSITIONS AND APPOINTMENTS**

Boston Medical Center, Assistant Biologist

Boston University, Professor

Pulmonary Research Foundation, Associate Member – No research resources and no funding held

Fuzhou University, Associate Professor

**OVERLAP STATEMENT**

There is scientific overlap between aim 2 of the European Commission funding and aim 4 of the application under consideration. If both are funded, Dr. Fitzgerald requests permission to discuss how to adjust the budget and scope of work for the pending proposal with agency staff. No other scientific, budgetary, and effort commitment overlap.

1. Generally, annual direct costs do not need to be reported, but this information may be requested by a Grants Management Specialist. [↑](#footnote-ref-1)